Skip Navigation LinksHome > January 2013 - Volume 19 - Issue 1 > Does Smoking Influence Crohn's Disease in the Biologic Era?...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.22959
Original Clinical Articles

Does Smoking Influence Crohn's Disease in the Biologic Era? The TABACROHN Study

Nunes, Tiago MD1,†; Etchevers, Maria Josefina MD1,†; Merino, Olga MD, PhD2; Gallego, Sonia MD3; García-Sánchez, Valle MD, PhD4; Marín-Jiménez, Ignacio MD, PhD5; Menchén, Luis MD5; Acosta, Manuel Barreiro-de MD, PhD6; Bastida, Guillermo MD7,†; García, Sara MD8; Gento, Elena MD8; Ginard, Daniel MD, PhD9; Gomollón, Fernando MD, PhD10; Arroyo, Maite MD, PhD10; Monfort, David MD11; García-Planella, Esther MD12; Gonzalez, Benito MD13; Loras, Carme MD, PhD14; Agustí, Carles MD1,†; Figueroa, Carolina MD1,†; Sans, Miquel MD, PhD1,†; for the TABACROHN Study Group of GETECCU, Spanish Working Group in Crohn's Disease and Ulcerative Colitis

Collapse Box

Abstract

Background: While most studies have found a negative effect of smoking on Crohn's disease (CD) phenotype, more recent data have failed to reproduce this association, which might be due to a current wider use of thiopurines and biologic therapy. The TABACROHN study aimed at defining the impact of smoking on CD in the largest published series.

Methods: This multicenter cross-sectional study included 1170 CD patients. Patients were classified as nonsmokers, current smokers, or former smokers according to their present smoking status. Clinical data regarding disease characteristics, treatment, and complications were collected.

Results: Smokers were more frequently under maintenance treatment when compared to nonsmokers. In addition, current smokers presented higher use of biologic drugs compared to nonsmokers. Tobacco exposure and a higher tobacco load were independent predictors of need for maintenance treatment and stenosing phenotype, respectively.

Conclusions: In the era of early and widespread use of immunosuppressants and biologics, tobacco exposure is an independent predictor of need for maintenance treatment, specifically biologic therapy. The wider use of biologics and immunosuppressants could account for the existence of no major differences in disease behavior and complications between nonsmokers and current smokers.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.